Martin Capital Partners LLC Has $1.45 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Martin Capital Partners LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 60.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,678 shares of the biopharmaceutical company’s stock after selling 82,008 shares during the quarter. Martin Capital Partners LLC’s holdings in Pfizer were worth $1,451,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Swiss National Bank boosted its stake in Pfizer by 0.6% in the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company’s stock worth $486,762,000 after purchasing an additional 100,900 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Pfizer by 11.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares in the last quarter. Empowered Funds LLC boosted its position in shares of Pfizer by 80.9% during the third quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company’s stock worth $14,709,000 after buying an additional 227,349 shares during the period. Addison Advisors LLC raised its position in Pfizer by 394.2% in the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after buying an additional 41,668 shares during the last quarter. Finally, KBC Group NV lifted its stake in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company’s stock valued at $89,872,000 after acquiring an additional 639,985 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.2 %

PFE stock opened at $25.88 on Wednesday. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The stock has a market cap of $146.64 billion, a P/E ratio of 34.97, a P/E/G ratio of 0.66 and a beta of 0.64. The stock’s fifty day simple moving average is $26.27 and its two-hundred day simple moving average is $27.79. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 EPS. Analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.65%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Wolfe Research began coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target on the stock. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.